




Vaxart, Inc.
Investor Relations Department
2500 Northwinds Parkway
Suite 100
Alpharetta, GA 30009
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: VXRT

| | |
|---------------|---|
| Last Trade: | 5.91 |
| Trade Time: | 10:06 AM ET Mar 19, 2018 |
| Change: | -0.39  (-6.175%) |
| Day Range | 5.91 - 6.25 |
| 52-Week Range | 4.74 - 11.88 |
| Volume | 3,630 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Vaxart is focused on developing oral recombinant protein vaccines administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart's oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. The Company is developing prophylactic vaccine candidates that target a range of infectious diseases, including norovirus, a widespread cause of acute gastrointestinal distress for which two Phase 1 human studies hav... [\(more\)](#)

Stock Information



Press Releases [\[View all \]](#)

- Mar 7, 2018*
[Vaxart Expands Intellectual Property Portfolio With U.S. Patent Allowance](#)
- Mar 2, 2018*
[Vaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious Diseases](#)
- Feb 14, 2018*
[Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc.](#)
- Feb 9, 2018*
[Aviragen Adjourns Special Meeting of Stockholders to Allow Stockholders to Consider Improved Merger Deal Terms](#)
- Feb 9, 2018*
[Vaxart Provides Merger Update](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Feb 26, 2018*
[Proxy Statement \(DEF 14A\)](#)
- Feb 6, 2018*
[Quarterly Report \(10-Q\)](#)